AIBILI-CEC (AIBILI- Clinical Trials Centre)
Coimbra, 3000-548, Portugal
NCT Number: NCT05112445
Retinal ischemia characterization in diabetes - RICHARD
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Coimbra, 3000-548, Portugal
RICHARD is a non-interventional observational cross-sectional and prospective study. Patients will attend their routine clinical appointments, with 2-years of follow-up. Type 2 diabetic individuals with retinopathy ETDRS DRSS grade 43 with IRMA or grade 47-53 will be recruited and examined using non-invasive methodologies.
The study will be performed at AIBILI Clinical Trials Centre (CEC). Demographic and systemic parameters, such as diabetes duration, medical history, medication, body mass index, and family history of medical conditions (particularly when related to cognitive decline) will be registered at baseline.
All subjects will undergo an annual complete non-invasive ophthalmological examination, which includes, best corrected visual acuity, 7-fields CFP to assess ETDRS DRSS level, structural SD-OCT, SD-OCTA, SS-OCTA and ultra-widefield fundus photography (UWF FP). An invasive ophthalmological examination, the Ultra-wide field fundus fluorescein angiography (UWF FFA) will be obtained from both eyes at baseline (V0, M0) only in subjects with ETDRS DRSS grade 43 for final eligibility (43+IRMA).
Ophthalmological examinations performed will be analyzed at AIBILI Coimbra Ophthalmology Reading Centre (CORC) and Centre for New Technologies e Medicine (CNTM).
Color fundus photography (7-fields) will be acquired at V0 (month 0, baseline, cross-sectional study), V2 (month 12) and V3 (month 24), and then graded and classified according to the ETDRS severity scale by CORC, to allow evaluation of retinopathy progression over two years of follow-up. . At baseline visit (V0) both eyes will be evaluated and the study eye will be selected according to ETDRS DRSS grade (43 with IRMA, 47 or 53). Only the study eye will be considered for the primary statistical analysis; other statistical analyses will include both eyes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Change from baseline to Month 12
Identify which baseline OCTA metrics and predict progression to PDR and/ or CI- DME best correlate with visual function.
Time frame: Change from baseline to Month 24
Identify which baseline OCTA metrics and predict progression to PDR and/ or CI- DME best correlate with visual function.
Association for Innovation and Biomedical Research on Light and Image
Other
Retinal Ischemia Characterization in Diabetes.
Acronym: RICHARD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07707856
Cardiovascular Diseases, Diabetes Complications
Banhā, Benha, Egypt
View Trial DetailsNCT04132401
Age-Related Macular Degeneration, Cardiovascular Diseases
Manresa, Barcelona, Spain
View Trial DetailsNCT04505566
Cardiovascular Diseases, Diabetes Complications
Nashville, Tennessee, United States
View Trial DetailsNCT07255326
Autoimmune Diseases, Cardiovascular Diseases
Faisalabad, Punjab Province, Pakistan
View Trial Details